These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31883413)

  • 1. Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation.
    Visentin J; Bachelet T; Aubert O; Del Bello A; Martinez C; Jambon F; Guidicelli G; Ralazamahaleo M; Bouthemy C; Cargou M; Congy-Jolivet N; Nong T; Lee JH; Sberro-Soussan R; Couzi L; Kamar N; Legendre C; Merville P; Taupin JL
    Am J Transplant; 2020 May; 20(5):1365-1374. PubMed ID: 31883413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation.
    Bachelet T; Martinez C; Del Bello A; Couzi L; Kejji S; Guidicelli G; Lepreux S; Visentin J; Congy-Jolivet N; Rostaing L; Taupin JL; Kamar N; Merville P
    Transplantation; 2016 Jan; 100(1):159-66. PubMed ID: 26262501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation.
    Visentin J; Guidicelli G; Bachelet T; Jacquelinet C; Audry B; Nong T; Dubois V; Moreau JF; Lee JH; Couzi L; Merville P; Taupin JL
    Transplantation; 2014 Oct; 98(7):738-44. PubMed ID: 25289917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation.
    Visentin J; Marroc M; Guidicelli G; Bachelet T; Nong T; Moreau JF; Lee JH; Merville P; Couzi L; Taupin JL
    Clin Transplant; 2015 May; 29(5):393-402. PubMed ID: 25683727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
    Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
    Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive virtual crossmatch with negative flow crossmatch results in two cases.
    Jacob EK; De Goey SR; Gandhi MJ
    Transpl Immunol; 2011 Jul; 25(1):77-81. PubMed ID: 21641997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Preformed Donor-Specific Anti-HLA-Cw and Anti-HLA-DP Antibodies on Acute Antibody-Mediated Rejection in Kidney Transplantation.
    Laboux T; Lenain R; Visentin J; Flahaut G; Chamley P; Provôt F; Top I; Kerleau C; Labalette M; Choukroun G; Couzi L; Blancho G; Hazzan M; Maanaoui M
    Transpl Int; 2023; 36():11416. PubMed ID: 38076227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessment of T Lymphocytes Crossmatches Results Prediction With Luminex Class I Single Antigen Flow Beads Assay.
    Visentin J; Bachelet T; Borg C; Franchini N; Nong T; Lee JH; Couzi L; Merville P; Guidicelli G; Taupin JL
    Transplantation; 2017 Mar; 101(3):624-630. PubMed ID: 27336398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.
    Senev A; Lerut E; Van Sandt V; Coemans M; Callemeyn J; Sprangers B; Kuypers D; Emonds MP; Naesens M
    Am J Transplant; 2019 Nov; 19(11):3100-3113. PubMed ID: 31062492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.
    Ata P; Canbakan M; Kara M; Özel L; Ünal E; Titiz Mİ
    Transplant Proc; 2012; 44(6):1652-5. PubMed ID: 22841237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
    Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
    Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival.
    ten Hoor GM; Coopmans M; Allebes WA
    Transplantation; 1993 Aug; 56(2):298-304. PubMed ID: 7689256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
    Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of pretransplant donor-specific antibodies reactive with intact or denatured human leucocyte antigen in kidney transplantation.
    Otten HG; Verhaar MC; Borst HP; van Eck M; van Ginkel WG; Hené RJ; van Zuilen AD
    Clin Exp Immunol; 2013 Sep; 173(3):536-43. PubMed ID: 23627692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General insufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients' medical treatment or underlying diseases.
    Schlaf G; Mauz-Körholz C; Ott U; Leike S; Altermann W
    Histol Histopathol; 2012 Jan; 27(1):31-8. PubMed ID: 22127594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.